Decreasing Interstage Mortality After the Norwood Procedure: A 30-Year Experience

Michelle Kaplinski, MD, MPH; Richard F. Ittenbach, PhD; Mallory L. Hunt, MD; Donna Stephan, BS; Shobha S. Natarajan, MD; Chitra Ravishankar, MD; Therese M. Giglia, MD; Jack Rychik, MD; Jonathan J. Rome, MD; Marlene Mahle, BS; Andrea T. Kennedy, BS; James M. Steven, MD; Stephanie M. Fuller, MD; Susan C. Nicolson, MD; Thomas L. Spray, MD; J. William Gaynor, MD; Christopher E. Mascio, MD

BACKGROUND: The superior cavo-pulmonary connection was introduced at our institution in 1988 for infants undergoing surgery for hypoplastic left heart syndrome. Patients with hypoplastic left heart syndrome remain at high risk for mortality in the time period between the Norwood procedure and the superior cavo-pulmonary connection. The primary objectives of this study were to compare interstage mortality across 4 eras and analyze factors that may impact interstage mortality.

METHODS AND RESULTS: Patients with hypoplastic left heart syndrome who underwent the Norwood procedure, were discharged from the hospital, and were eligible for superior cavo-pulmonary connection between January 1, 1988, and December 31, 2017, were included. The study period was divided into 4 eras based on changes in operative or medical management. Mortality rates were estimated with 95% CIs. Adjusted and unadjusted logistic regression models were used to identify risk factors for mortality. There were 1111 patients who met the inclusion criteria. Overall, interstage mortality was 120/1111 (10.8%). Interstage mortality was significantly lower in era 4 relative to era 1 (4.6% versus 13.4%; P=0.02) during the time that age at the superior cavo-pulmonary connection was the lowest (135 days; P<0.01) and the interstage monitoring program was introduced. In addition, use of the right ventricle to pulmonary artery shunt was associated with decreased interstage mortality (P=0.02) and was more routinely practiced in era 4.

CONCLUSIONS: During this 30-year experience, the risk of interstage mortality decreased significantly in the most recent era. Factors that coincide with this finding include younger age at superior cavo-pulmonary connection, introduction of an interstage monitoring program, and increased use of the right ventricle to pulmonary artery shunt.

Key Words: hypoplastic left heart syndrome • interstage monitoring program • interstage period

Hypoplastic left heart syndrome (HLHS) and similar structural variants were almost uniformly fatal until the advent of the Norwood procedure (NP). The NP was introduced as the initial surgical palliation in the newborn period and was followed by the Fontan procedure several years later, as a 2-staged palliation. After high mortality rates during the Fontan operation, a 3-staged surgical approach for HLHS was established in 1988 in which the superior cavo-pulmonary connection (SCPC) was completed between the NP and the Fontan.

With this approach, long-term survival for patients with HLHS has significantly improved. However, there remains a high risk of mortality in patients with HLHS during the interstage period, between the NP discharge and admission for SCPC, with mortality rates of 5% to 20%. One strategy introduced to help reduce interstage mortality was an interstage monitoring program (ISMP), where infants are closely monitored by a dedicated team of healthcare providers and the family. Early results from single center retrospective studies demonstrated dramatic decreases in interstage mortality following initiation of an ISMP. Yet controversy remains regarding the efficacy of these programs after a large multicenter study demonstrated no decrease in mortality with ISMPs. Other strategies...
used to decrease interstage mortality included using a right ventricle to pulmonary artery (RV-PA) shunt in place of a modified Blalock Taussig (BT) shunt or decreasing the time between the NP and SCPC; however, the long-term benefits and risks remain unclear.4,5,10

The objectives of this study were to examine the overall incidence of interstage mortality during a 30-year period, evaluate interstage mortality across 4 predetermined eras (based on changes in operative or medical management), and analyze the impact of patient characteristics and operative factors on interstage mortality.

METHODS

Study Design
Because of the sensitive nature of the data collected for this study, data will not be available publicly. This was a retrospective chart review that included all patients with HLHS (and variants) who underwent NP, were discharged from the hospital, and were eligible for SCPC between January 1, 1984, and December 31, 2017. Patients excluded were those who underwent 2-ventricle conversion or orthotopic heart transplantation before SCPC, died before Norwood discharge, or underwent SCPC during NP hospitalization. All patients who underwent NP before 1988 were excluded because routine SCPC was not performed at that time. Patients followed at other institutions who were known to be alive at 1 year without information about SCPC were considered survivors. Patients who were discharged alive but with no further follow-up information were excluded. This study was approved by the Children’s Hospital of Philadelphia Institutional Review Board for the Protection of Human Subjects; requirement for subject-informed consent was waived because it was not needed for this retrospective study.

The study period was divided into the following 4 eras based on changes in operative or medical management: era 1 (1988–1994, initial use of SCPC), era 2 (1995–2001, change in surgical team), era 3 (2002–2010, introduction of RV-PA shunt), and era 4 (2011–2017, introduction of ISMP). Because of the unique and often theoretically distinct practice patterns associated with each era, the decision was made at the design stage of the study to treat era as a categorical as opposed to an interval or ordinal variable, with conceptually distinct eras for mortality estimates as well as modeling. Data on patient characteristics were abstracted from paper charts, electronic medical records, and clinical registries.

Statistical Analysis

Data analysis proceeded in 3 distinct phases: a descriptive phase in which measures of central tendency, variability, and association were computed for all relevant variables in the data set; an estimation phase in which mortality estimates for interstage deaths were computed and compared by era; and a risk-modeling phase to identify risk factors for interstage mortality among the cohort. All data were analyzed using SAS v9.4 (SAS Institute, Cary, NC).

Descriptive Phase

Descriptive statistics were computed using parametric as well as nonparametric measures of central tendency, variability, and association for all relevant measures to better understand the data. Except for 2 variables, ascending aorta size and gestational age, for which our data were 85% and 93% complete, respectively, missing or incomplete data were minimal (0.2%–0.5%). Hence, no further adjustments were made for missing or incomplete data.
**Estimation Phase**

Mortality rates were computed for the interstage period (0=alive, 1=deceased) using standard binomial proportions and corresponding 95% CIs overall and by era. Rates across eras were then compared using a logistic regression model with a Tukey–Kramer post hoc adjustment for multiplicity. Average age at SCPC and average age at death were also estimated for the entire cohort and compared by era, complete with empirically derived 95% CIs. Wilcoxon rank-sum tests were used as both an omnibus test in its generalized form (Kruskal–Wallis) and a pairwise follow-up test of significance because of the skewed and non-normative nature of the distributions.

**Risk-Modeling Phase**

In the risk-modeling phase, 2 sets of logistic regression models were used. In the first set, mortality was regressed onto era as a polychotomous predictor and then onto each of 14 different covariates individually after adjusting for era as the lone confounder for all 1111 patients. A final, best-fitting, multiple covariate model for our primary hypothesis was then selected from among candidate predictors with \( P < 0.10 \), resulting in a model consisting of era, gestational age, and race as testable covariates. A subsequent, secondary analysis was conducted to estimate the impact of shunt type on mortality after adjusting for era as the lone confounder, with era 3 as the new reference group. This cohort included all 526 patients undergoing the NP once the RV-PA shunt was introduced into care. Similar to the primary model, a final, best-fitting logistic regression model was also specified and tested on the reduced sample, with mortality as the outcome and shunt type as the testable covariate and era, gestational age, use of ECMO, and race as informative covariates. This model was then followed up with a simple contingency table test (\( \chi^2 \)) comparing mortality rates between the BT/central shunt group and the RV-PA shunt group for the period in which the RV-PA shunt was available for use. All models tested here were compared and evaluated using model-specific and term-specific Wald (\( \chi^2 \)) statistics as well as Akaike information criterion and log-likelihood comparisons using full and reduced models; all tests were conducted at the unadjusted \( \alpha = 0.05 \) level.

**RESULTS**

During the study period of January 1, 1984, to December 31, 2017, there were 1772 NPs performed. There were 215 patients who were excluded because they had their NP between 1984 and 1987, before routine interim staging. There were 1193 NP hospital survivors during or after 1988. Of those survivors, 14 were excluded because of biventricular conversion, 2 for orthotopic heart transplantation before NP discharge, 6 for orthotopic heart transplantation before SCPC, and 14 for SCPC before NP discharge. A total of 46 patients were lost to follow-up. Therefore, 1111 patients were available for interstage analysis. Of those, 991 underwent a SCPC and survived, and 120 infants died during the interstage period (after NP discharge without any intervention at <1 year) (Figure 1). If a patient was known to be alive at 1 year but there was no information regarding subsequent operations, he or she was considered a survivor.

The most common diagnosis was HLHS with aortic atresia and mitral atresia (33%) followed by HLHS

![Figure 1. Patient selection.](image-url)

NP indicates Norwood procedure; and SCPC, superior cavopulmonary connection.
variants (31%). Nearly 12% of patients had a suspected or confirmed genetic abnormality. Anomalous pulmonary venous drainage and significant (moderate or severe) atrioventricular valve regurgitation before the NP were relatively uncommon (4% and 10%, respectively), whereas 13% of our patients had an intact or restrictive atrial septum. The large majority of patients underwent placement of a modified BT or central shunt (83%). Additional patient characteristics are provided in Table 1.

Overall, interstage mortality was 120/1111 (10.8%) and was stable throughout most of the study period, decreasing in the most recent era relative to all others: era 1 (13.4%), era 2 (10.4%), era 3 (11.6%), and era 4 (7.8%).

Table 1. Patient Characteristics (N=1111)

| Variable                                      | Frequency                        | No (%) | Yes (%) | Missing | No. | Median | Q25, Q75 |
|-----------------------------------------------|----------------------------------|--------|---------|---------|------|--------|----------|
| Ascending aorta, mm                           |                                  | 923    | 3.0     | 2.0, 5.0|      | 3.0    |          |
| Age at Norwood, d                             |                                  | 1111   | 5.0     | 3.0, 7.3|      | 5.0    |          |
| Birth weight, g                               |                                  | 1041   | 3.2     | 2.9, 3.5|      | 3.2    |          |
| CPB time, min                                 |                                  | 1111   | 39.0    | 37.0, 47.0|    | 39.0   |          |
| DHCA time, min                                |                                  | 1111   | 49.0    | 40.0, 59.0|    | 49.0   |          |
| Gestational age, wk                           |                                  | 1029   | 39.0    | 38.0, 39.0|    | 39.0   |          |
| LOS, d                                        |                                  | 1111   | 19.0    | 13.0, 31.0|    | 19.0   |          |
| Total support time, min                       |                                  | 1111   | 89.0    | 79.0, 105.0|   | 89.0   |          |
| Anomalous pulmonary venous drainage           |                                  | 1067   | 96.0    | 39 (3.5) | 5 (0.4)|        |          |
| Atrioventricular valve regurgitation*         |                                  | 1000   | 90.0    | 111 (10.0) |    | 111    |          |
| Intact or restrictive atrial septum †         |                                  | 957    | 86.1    | 149 (13.4) | 5 (0.4)|        |          |
| Era                                           |                                  |        |         |         |      |        |          |
| 1988–1994 (era 1)                             |                                  | 352    | 31.7    |         |      | 31.7   |          |
| 1995–2001 (era 2)                             |                                  | 230    | 20.7    |         |      | 20.7   |          |
| 2002–2010 (era 3)                             |                                  | 355    | 32.0    |         |      | 32.0   |          |
| 2011–2017 (era 4)                             |                                  | 174    | 15.7    |         |      | 15.7   |          |
| Genetic anomaly                               |                                  |        |         |         |      |        |          |
| Normal                                        |                                  | 981    | 88.3    |         |      | 88.3   |          |
| Suspect/abnormal                              |                                  | 130    | 11.7    |         |      | 11.7   |          |
| Hypoplastic left heart syndrome               |                                  |        |         |         |      |        |          |
| Aortic atresia/mitral atresia                 |                                  | 370    | 33.3    |         |      | 33.3   |          |
| Aortic atresia/mitral stenosis                |                                  | 171    | 15.4    |         |      | 15.4   |          |
| Aortic stenosis/mitral atresia; Aortic stenosis/mitral stenosis | | 220 | 19.8 | | | | |
| HLHS variant                                  |                                  | 348    | 31.3    |         |      | 31.3   |          |
| Missing                                       |                                  | 2      | 0.2     |         |      | 0.2    |          |
| Race                                          |                                  |        |         |         |      |        |          |
| White                                         |                                  | 790    | 71.1    |         |      | 71.1   |          |
| Black                                         |                                  | 161    | 14.5    |         |      | 14.5   |          |
| Other                                         |                                  | 160    | 14.4    |         |      | 14.4   |          |
| Sex                                           |                                  |        |         |         |      |        |          |
| Female                                        |                                  | 412    | 37.1    |         |      | 37.1   |          |
| Male                                          |                                  | 699    | 62.9    |         |      | 62.9   |          |
| Shunt type                                    |                                  |        |         |         |      |        |          |
| Blalock-Taussig/central                       |                                  | 918    | 82.6    |         |      | 82.6   |          |
| Right ventricle-pulmonary artery              |                                  | 183    | 16.5    |         |      | 16.5   |          |
| Missing                                       |                                  | 10     | 0.9     |         |      | 0.9    |          |

CPB indicates cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; HLHS, hypoplastic left heart syndrome; LOS, length of stay; Q25, first quartile; and Q75, third quartile.

*Yes=moderate or severe.
†Yes=yes or restrictive.
Kapinski et al Interstage Mortality and Monitoring (4.6%) (Figure 2, Table 2). Whereas age at SCPC decreased significantly across the 4 eras (from 208 days in era 1 to 135 days in era 4), there were no statistically significant differences among the 4 eras for age at death (Figure 2, Table 3).

Birth weight, gestational age, length of stay, genetic anomaly, and race (all \( P \leq 0.05 \)) were identified as risk factors for interstage mortality using single covariate adjusted (era) logistic regression models (Table 4). A final, best-fitting, multiple logistic regression model indicated that gestational age (\( P = 0.04 \)) and race (\( P < 0.01 \)) were both associated with interstage mortality after adjusting for era (\( P < 0.01 \)). Importantly, when compared with era 1, era 4 had a significantly lower mortality rate (\( P < 0.01 \)), corresponding to both the introduction of the ISMP and the shortest average time period between the NP and SCPC (Tables 3 and 4, Figure 3). A subsequent, secondary analysis was conducted to estimate the relationship between shunt type (\( P = 0.02 \)) and interstage mortality after adjusting for era (\( P = 0.07 \)): gestational age (\( P < 0.01 \)), use of ECMO (\( P = 0.02 \)), and race (\( P < 0.01 \)); all statistically significant contributors to the final, secondary model. With respect to shunt type, specifically, interstage survival was higher in patients with RV-PA shunts (95.6%) than BT or central shunts (88.0%). RV-PA shunts were first used in era 3 and accounted for 27.4% of shunt types in era 3 and 50.0% of shunt types in era 4.

**DISCUSSION**

This is the largest single-center cohort assessing the risk of mortality during the interstage period after NP discharge and before SCPC for patients with HLHS. During a 30-year time period at our institution, the overall interstage mortality rate was 10.8%, which is similar to other studies, including the multicenter Single Ventricle Reconstruction Trial.\(^5\)\(^,\)\(^11\)\(^-\)\(^14\) Interestingly, we found that the risk of interstage mortality after NP has decreased significantly in the most recent era. This corresponds to several changes in clinical and surgical management, including the shortest average time period between the NP and SCPC, the introduction of the ISMP program, and an increased use of the RV-PA shunt. No other era for which there was a major alteration in medical or surgical management demonstrated a statistically significant decrease in interstage mortality.
Age at SCPC decreased significantly throughout all 4 eras. It is important to note that an integral component of our ISMP is routine scheduling of the SCPC at ≈4 months of age, so the ISMP and earlier time at SCPC are connected. Several studies have shown similar findings, demonstrating that patients with early SCPC have less interstage mortality.15,16 In addition, a recent study from our institution

| Years                  | Age at SCPC (d) | Age at Death (d) |
|------------------------|----------------|-----------------|
|                        | No. | Median (95% CI) | No. | Median (95% CI) |
| Entire cohort          | 957 | 179 (174–183)   | 120 | 103.5 (84–122)  |
| 1988–1994 (era 1)      | 298 | 208 (202–216)   | 47  | 118.0 (88–151)  |
| 1995–2001 (era 2)      | 194 | 189 (183–195)   | 24  | 73.0 (55–121)   |
| 2002–2010 (era 3)      | 304 | 165 (160–170)   | 41  | 105.0 (75–135)  |
| 2011–2017 (era 4)      | 161 | 135 (132–138)   | 8   | 43.0 (22–244)   |

Wilcoxon rank-sum tests for all pairwise comparisons for each variable resulted in statistically significant differences for all ages at SCPC comparisons (P<0.01), but not for any age at death comparisons after adjustment for multiplicity. SCPC indicates Superior Cavo-Pulmonary Connection.

| Potential Risk Factors                        | No. | Adjusted for Era | Best-Fitting Multiple Covariate Model |
|-----------------------------------------------|-----|-----------------|--------------------------------------|
| Ascending aorta, mm                           | 923 | −0.09 (0.06)    | OR (95% CI) 0.92 (0.81–1.04) P 0.18 |
| Age at Norwood, d                             | 1111| 0.00 (0.00)     | OR (95% CI) 1.00 (0.99–1.01) P 0.82 |
| Atrioventricular valve regurgitation (none)   | 1111| 0.08 (0.16)     | OR (95% CI) 1.18 (0.64–2.20) P 0.59 |
| Birth weight, kg                              | 1041| −0.43 (0.17)    | OR (95% CI) 0.65 (0.46–0.91) P 0.01 |
| Era                                           | 1111| 0.03            | OR (95% CI) P 0.01                    |
| 1988–1994 (reference)                         |     |                 |                                      |
| 1995–2001                                     | 1111| 0.12 (0.19)     | OR (95% CI) 0.76 (0.45–1.28) P 0.53 |
| 2002–2010                                     | 1111| 0.24 (0.17)     | OR (95% CI) 0.85 (0.54–1.33) P 0.16 |
| 2011–2017                                     | 1111| −0.76 (0.28)    | OR (95% CI) 0.31 (0.14–0.68) P 0.01 |
| Cardiopulmonary bypass time, min              | 1111| −0.01 (0.00)    | OR (95% CI) 0.99 (0.98–1.00) P 0.13 |
| Deep hypothermic circulatory arrest time, min | 1111| −0.01 (0.00)    | OR (95% CI) 0.99 (0.98–1.00) P 0.17 |
| Gestational age, wk                           | 1029| −0.12 (0.05)    | OR (95% CI) 0.89 (0.80–0.98) P 0.02 |
| Genetic anomaly (none)                        | 1111| 0.27 (0.14)     | OR (95% CI) 1.70 (0.99–2.92) P 0.05 |
| Hypoplastic left heart syndrome subtype        | 1109|                 | OR (95% CI) 0.98                    |
| Aortic atresia/mitral atresia (reference)     |     | −0.09 (0.21)    | OR (95% CI) 0.89 (0.49–1.63) P 0.68 |
| Aortic atresia/mitral stenosis                |     | 0.01 (0.18)     | OR (95% CI) 0.98 (0.58–1.69) P 0.96 |
| Variant                                       |     | 0.05 (0.16)     | OR (95% CI) 1.03 (0.64–1.65) P 0.74 |
| Intact atrial septum (reference: no)          | 1106| −0.02 (0.14)    | OR (95% CI) 0.97 (0.55–1.70) P 0.90 |
| LOS, d                                        | 1106| 0.01 (0.00)     | OR (95% CI) 1.01 (1.00–1.01) P 0.01 |
| Race                                          | 1111|                 | OR (95% CI) P <0.01                  |
| White (reference)                             |     |                 |                                      |
| Black                                         | 1106| −0.01 (0.18)    | OR (95% CI) 1.57 (0.93–2.65) P 0.96 |
| Other                                         | 1106| 0.47 (0.17)     | OR (95% CI) 2.54 (1.56–4.15) P <0.01|
| Sex (reference: female)                       | 1111| −0.03 (0.10)    | OR (95% CI) 0.94 (0.63–1.38) P 0.74 |
| Total support time, min                       | 1111| −0.00 (0.00)    | OR (95% CI) 1.00 (0.99–1.00) P 0.23 |

Values reported here as 0.00 were rounded to 2 decimal places for consistency of reporting and to reduce the complexity of the table. LOS indicates length of stay.

*All single covariate models were adjusted for era; however, era was also tested individually as a categorical covariate with no additional adjustments.
Kaplinski et al Interstage Mortality and Monitoring

found that younger age at SCPC was not associated with higher postoperative mortality or longer length of stay.16 Not all studies, however, have determined that earlier SCPC is beneficial, and some suggest it does result in longer length of stay.17 Thus there may be an optimal time that is just long enough and just short enough after NP to benefit the patient. Meza et al suggest that the timing of SCPC is best after 3 months but before 6 months for patients who are not high risk, and others have found that patients who are older at the time of SCPC have worse outcomes at the Fontan operation.18,19

This study is consistent with other retrospective, single-center studies that have shown a decrease in interstage mortality following the introduction of an ISMP.7,20–22 Although the multicenter study by Oster et al using data from the National Pediatric Cardiology Quality Improvement Collaborative did not initially demonstrate a survival benefit with ISMPs, subsequent analyses have shown a benefit.5,23 To note, we rarely keep patients hospitalized after the Norwood operation during the interstage period, with only 14 patients (1%) during the 30-year period remaining hospitalized before the SCPC operation. This practice did not change with the introduction of the ISMP. This number is less than that reported in the Single Ventricle Reconstruction trial and less than other large pediatric medical centers.5,24 Our robust ISMP includes daily weight and oxygen saturation measurements as well as mandatory weekly medical follow-up and weekly calls with the dedicated program nurse practitioner and dietician.16 This rigorous program may account for the discrepancy in findings from this study and previously reported data.

A decrease in interstage mortality with the use of RV-PA shunts compared with BT or central shunts was first reported by Sano et al and has since been confirmed in several studies.5,25,26 Our subanalysis demonstrated that patients with RV-PA shunts have improved survival compared with BT or central shunts. In addition, there was an increase in use of RV-PA shunts in era 4, during the same time as the initiation of the ISMP and shortest length of time between the NP and SCPC. This topic remains controversial, however, as several other studies have demonstrated no hemodynamic or survival benefit with an RV-PA shunt.16,27,28

Independent patient characteristics that have been associated with interstage mortality in other studies were also confirmed in our analysis and include earlier era of operation, lower birth weight, younger gestational age, confirmed or suspected genetic anomaly, race, and longer length of stay. On multivariate analysis, those who were born in an era before the initiation of the ISMP, those who were born at an earlier gestation age, and those who reported a race other than Black or White were still associated with higher interstage mortality. Many of those risk factors represent high-risk cohorts that may require specific management changes, including remaining in the hospital during the interstage period and undergoing an earlier SCPC or a primary hybrid procedure with a more extensive second operation (combined NP and SCPC).

Our study has several limitations. Although this is one of the largest studies of patients who underwent an NP, it is a single-center retrospective study. Despite our significant findings, we cannot determine the relative impact of each individual factor. Some of

Figure 3. Interstage mortality after the introduction of a right ventricle to pulmonary artery shunt and interstage monitoring.

ISMP indicates interstage monitoring program; and RVPA, right ventricle to pulmonary artery shunt.
the findings that differ from multicenter studies may be attributed to differences in practice at our institution. Because this study spanned 3 decades, there may be other changes in clinical practice for which we did not account that could have affected our findings.

In this cohort, we demonstrated a significant decrease in interstage mortality in the most recent era. This decline in mortality is associated with earlier age at SCPC operation, introduction of an ISMP, and increased use of the RV-PA shunt. Although not causative, these factors may have contributed to the significant decrease in interstage mortality in the most recent era. Because age at SCPC and ISMP in relation to interstage mortality are temporally related, it is not possible to determine their relative contributions to the observed decrease in interstage mortality.

ARTICLE INFORMATION
Received April 2, 2020; accepted August 20, 2020.

Affiliations
From the Division of Pediatric Cardiology, Department of Pediatrics, Lucile Packard Children’s Hospital, Stanford University, Palo Alto, CA (M.K.); Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children’s Hospital, University of Cincinnati College of Medicine, Cincinnati, OH (R.F.I.); Division of Cardiothoracic Surgery, Department of Surgery (M.L.H., D.S., M.M., A.T.K., S.M.F., T.L.S., J.W.G., C.E.M.); Division of Cardiology, Department of Pediatrics (S.S.N., C.R., T.M.G., J.R., J.J.R.) and Division of Cardiac Anesthesia, Department of Anesthesiology and Critical Care Medicine, The Children’s Hospital of Philadelphia, and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.M.S., S.C.N.).

Sources of Funding
This work was supported by the Daniel M. Tabas and Alice Langdon Warner Endowed Chairs in Pediatric Cardiothoracic Surgery.

Disclosures
None.

REFERENCES
1. Gillum RF. Epidemiology of congenital heart disease in the United States. Am Heart J. 1994;127:919–927.
2. Norwood W, Jacobs ML. Fontan’s procedure in two stages. Am J Surg. 1993;166:548–551.
3. Pasquali SK. Reexamining interstage home monitoring after the Norwood operation. Circulation. 2015;132:475–478.
4. Tabbutt S, Ghanayem N, Ravishankar C, Sleeper LM, Cooper DS, Frank DU, Lu M, Pizarro C, Frommelt P, Goldberg GS, et al. Risk factors for hospital morbidity and mortality after the Norwood procedure: a report from the Pediatric Heart Network Single Ventricle Reconstruction Trial. J Thorac Cardiovasc Surg. 2012;144:882–895.
5. Ghanayem NS, Allen KR, Tabbutt S, Atz AM, Clabby ML, Cooper DS, Eghtesady P, Frommelt P, Gruber PJ, Hill KD, et al. Intersstage mortality after the Norwood procedure: results of the multicenter Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg. 2012;144:896–908.
6. Mahle WT, Spray TL, Gaynor JW, Clark BJ. Unexpected death after reconstructive surgery for hypoplastic left heart syndrome. Ann Thorac Surg. 2001;71:61–65.
7. Ghanayem NS, Cava JR, Jaquiss RDB, Tweddell JS. Home monitoring of infants after stage one palliation for hypoplastic left heart syndrome. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:32–38.
8. Rudd NA, Frommelt MA, Tweddell JS, Hehir DA, Mussatto KA, Frontier KD, Slicker JA, Bartz PJ, Ghanayem NS. Improving interstage survival after Norwood operation: outcomes from 10 years of home monitoring. J Thorac Cardiovasc Surg. 2014;148:1540–1547.
9. Oster ME, Ehrlich A, King E, Petit CJ, Clabby M, Smith S, Glanville M, Anderson J, Darbie L, Beekman RH. Association of interstage home monitoring with mortality, readmissions, and weight gain. Circulation. 2015;132:502–508.
10. Bates KE, Yu S, Lowery R, Pasquali SK, Brown DW, Manning PB, Uzark K. Examining variation in interstage mortality rates across the National Pediatric Cardiology Quality Improvement Collaborative: do lower-mortality centres have lower-risk patients? Cardiol Young. 2018;28:1031–1036.
11. Hehir DA, Dominguez TE, Ballweg JA, Ravishankar C, Marino BS, Bird GL, Nicolson SC, Spray TL, Gaynor JW, Tabbutt S. Risk factors for interstage death after stage 1 reconstruction of hypoplastic left heart syndrome and variants. J Thorac Cardiovasc Surg. 2008;136:94–99.
12. Tabbutt S, Dominguez TE, Ravishankar C, Marino BS, Gruber PJ, Wemovsky G, Gaynor JW, Nicolson SC, Spray TL. Outcomes after the stage 1 reconstruction comparing the right ventricular to pulmonary artery conduit with the modified Blalock Taussig shunt. Ann Thorac Surg. 2005;80:1582–1591.
13. Cua CL, Thiagarajan RR, Gauvreau K, LaI L, Costello J, Wessel D, del Nido P, Mayer J, Newburger J, Laussen P. Early postoperative outcomes in a series of infants with hypoplastic left heart syndrome undergoing stage I palliation operation with either modified Blalock-Taussig shunt or right ventricle to pulmonary artery conduit. Pediatr Crit Care Med. 2006;7:238–244.
14. Simsic JM, Bradley SM, Stroud MR, Atz AM. Risk factors for interstage death after the Norwood procedure. Pediatr Cardiol. 2005;26:400–403.
15. Hill GD, Rudd NA, Ghanayem NS, Hehir DA, Bartz PJ. Center variability in timing of stage 2 palliation and association with interstage mortality: a report from the National Pediatric Cardiology Quality Improvement Collaborative. Pediatr Cardiol. 2016;37:1516–1524.
16. Gardner MM, Mercer-Rosa L, Faerber J, D’Ilenzo MP, Bates KE, Stagg A, Natarajan SS, Szwast A, Fuller S, Mascio CE, et al. Association of a home monitoring program with interstage and stage 2 outcomes. J Am Heart Assoc. 2019;8:e010783. DOI: 10.1161/JAHA.118.010783.
17. Cnota JF, Allen KR, Colan S, Covitz W, Graham EM, Hehir DA, Levine JO, Margossian R, Mcrindle BW, Minich LL, et al. Superior caval pulmonary anastomosis timing and outcomes in infants with single ventricle. J Thorac Cardiovasc Surg. 2013;145:1288–1296.
18. Meza JM, Hickey E, Mcrindle B, Blackstone E, Anderson B, Overman D, Kiklin JK, Karamoulo T, Caldarone C, Kim R, et al. The optimal timing of stage-2-palliation after the Norwood operation. Ann Thorac Surg. 2018;105:193–199.
19. Vitanova K, Shiraishi S, Mayr B, Beran E, Cleuizou J, Strbad M, Rohlig C, Hager A, Horer J, Lange R, et al. Impact of characteristics at stage-2-palliation on outcome following Fontan completion. Pediatr Cardiol. 2019;40:1476–1487.
20. Hansen JH, Furck AK, Petko C, Buchholz-Berdau R, Voges I, Schewe J, Rickers C, Kramer HH. Use of surveillance criteria reduces interstage mortality after the Norwood operation for hypoplastic left heart syndrome. Eur J Cardiothorac Surg. 2012;41:1013–1018.
21. Siehr SL, Norris JK, Bushnell JA, Ramamoorthy C, Reddy VM, Hanley FL, Wright GE. Home monitoring program reduces interstage mortality after the modified Norwood procedure. J Thorac Cardiovasc Surg. 2014;147:718–723.
22. Schidlow DN, Anderson JB, Kitzner TS, Beekman RH, Jenkins KJ, Kugler JD, Martin GR, Neish SR, Rosenthal GL, Lannon C. Variation in interstage outpatient care after the Norwood procedure: a report from the joint council on Congenital Heart Disease National Quality Improvement Collaborative. Congenit Heart Dis. 2011;6:98–107.
23. Anderson JB, Beekman RH, Kugler JD, Rosenthal GL, Jenkins KJ, Kitzner TS, Martin GR, Neish SR, Brown DW, Mangeot C, et al. Improvement in interstage survival in a national pediatric cardiology learning network. Circ Cardiovasc Qual Outcomes. 2015;8:438–438.
24. Tadphale SD, Tang X, EliHasan NO, Beam B, Prochan P. CavoPulmonary anastomosis during same hospitalization as stage 1 Norwood/hybrid palliative surgery. Ann Thorac Surg. 2017;103:1285–1291.
25. Sano S, Ishino K, Kawada M, Arai S, Kasahara S, Asai T, Masuda Z, Takeuchi M, Ohtsuki S. Right ventricle-pulmonary artery shunt in first-stage palliation of hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2003;126:504–509.
26. Ohye RG, Schonbeck JV, Eghtesady P, Laussen PC, Pizarro C, Shrader P, Frank DI, Graham EM, Hill KD, Jacobs JP, et al. Cause, timing, and location of death in the Single Ventricle Reconstruction Trial. J Thorac Cardiovasc Surg. 2012;144:907–914.

27. Ghanayem NS, Jaquiss RDB, Cava JR, Frommelt PC, Mussatto KA, Hoffman GM, Tweddell JS. Right ventricle-to-pulmonary artery conduit versus Blalock-Taussig shunt: a hemodynamic comparison. Ann Thorac Surg. 2006;82:1603–1609.

28. Ballweg JA, Dominguez TE, Ravishankar C, Gaynor JW, Nicolson SC, Spray TL, Tabbutt S. Contemporary comparison of the effect of shunt type in hypoplastic left heart syndrome on the hemodynamics and outcome at Fontan completion. J Thorac Cardiovasc Surg. 2010;140:537–544.